Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509002 · ClinicalTrials.gov registry record · Phase 2
Iressa Study in Patients With Salivary Gland Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00509002: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00509002 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00509002, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if ZD1839 (Iressa®, gefitinib can help to shrink or slow the growth of advanced, recurrent, or metastatic salivary gland cancer. The safety of this drug will also be studied.
Interventions
- DRUG Gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2004-05 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00509002
The ClinicalTrials.gov registry entry for NCT00509002 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gefitinib is the first listed.
NCT00509002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00509002 about?
NCT00509002 is a clinical study titled "Iressa Study in Patients With Salivary Gland Cancer". The goal of this clinical research study is to learn if ZD1839 (Iressa®, gefitinib can help to shrink or slow the growth of advanced, recurrent, or metastatic salivary gland cancer. The safety of this drug will also be studied.
What is the current status of trial NCT00509002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2004-05. Estimated completion is 2016-09.
What interventions are being tested in trial NCT00509002?
The interventions under investigation include: Gefitinib (DRUG).
Who is sponsoring clinical trial NCT00509002?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.